Solid Tumor Targeting CAR-T Development Service with Inducible Caspase-9 (iCas9) Suicide Gene System

The iCas9 suicide gene system effectively addresses the limitations of conventional safety switches in CAR-T therapy, such as reliance on cell division and significant bystander killing effects, which often lead to imprecise control and potential safety risks. Creative Biolabs' Solid Tumor Targeting CAR-T Development Service with Inducible Caspase-9 (iCas9) Suicide Gene System offers end-to-end development support for the construction of CAR-T cells targeting complex antigens. Our service delivers multiple advantages: the iCas9 system enables rapid clearance of transduced cells, induces apoptosis independent of the cell cycle, and exhibits minimal bystander effects, thereby significantly enhancing treatment safety without compromising efficacy.

Introduction

The iCas9 suicide gene system is a genetic safety strategy that enables precise and rapid elimination of transplanted cells by activating the caspase-9 apoptotic pathway via a chemical inducer of dimerization (CID). In CAR-T therapy, this system serves as a highly efficient safety switch, significantly mitigating risks such as on-target/off-tumor toxicity. By triggering apoptosis in a cell cycle-independent manner and exhibiting minimal bystander effects, it enhances both controllability and safety in the treatment of challenging targets like solid tumors, thereby broadening the therapeutic window and expanding the potential applications of CAR-T therapy.

Fig.1 iCasp9 activation enables controlled depletion of transduced cells.¹

Solid Tumor Targeting CAR-T Development Service with Inducible Caspase-9 (iCas9) Suicide Gene System at Creative Biolabs

Creative Biolabs' Solid Tumor Targeting CAR-T Development Service with Inducible Caspase-9 (iCas9) Suicide Gene System is designed to mitigate these risks by seamlessly integrating the iCas9 suicide gene system into your therapeutic construct. Our service provides a rapid and precise "kill switch" capability, ensuring patient safety in the event of severe adverse effects like Cytokine Release Syndrome (CRS) or unexpected normal tissue destruction.

What We Can Offer

We provide validated ablation kinetics, stringent bystander effect assessment, optimized bicistronic vector designs, and stoichiometric co-expression systems, ensuring both therapeutic potency and clinical-grade controllability.

Our Service Process

Required Starting Materials:

• Target Antigen Sequence: The full amino acid or nucleic acid sequence of the solid tumor-specific antigen that the CAR-T cell should recognize.
• Desired CAR Architecture: Any preliminary single-chain variable fragment (scFv) sequence or specific design preferences, such as preferred co-stimulatory domains or signaling domains.
• T Cell Source: If ex vivo development is required, we need information on the desired T cell source (e.g., donor PBMCs, patient cells, or established T cell lines).

Key Steps:

Final Deliverables:

• CAR-iCas9 T cells.
• Comprehensive assays data.

Key Advantages

• Customized Design and Engineering: We offer full customization of CAR structure, including the precise selection of scFv sequences and co-stimulatory domains to maximize efficacy against your unique solid tumor antigen.
• Integrated and Validated Safety Switch: Guaranteed, high-efficiency co-expression of the CAR construct with the iCas9 or RapaCaspase-9 safety gene, providing an essential, rapid-response control mechanism for trials.

FAQs

Why Choose Us?

Creative Biolabs provides integrated CAR-T solutions for solid tumors, uniquely combining the iCas9 suicide switch for rapid safety control with optimized CAR design. Our platform balances potent antitumor activity against challenging targets with validated risk mitigation, enabling you to advance novel therapies with enhanced efficacy and safety.

Customer Reviews

"Using Creative Biolabs' Solid Tumor Targeting CAR-T Development Service in our research has significantly improved the speed and reliability of our safety mitigation strategy. The iCas9 system's clinically proven ability to clear T cells within 30 minutes is non-negotiable for our Phase I protocols, especially when targeting antigens with known off-tumor risks." D****a M.

"Creative Biolabs recommended the CD28 co-stimulatory domain over 4-1BB for our solid tumor target based on their comparative data, resulting in a higher observed cytokine release and superior in vivo tumor control in our xenograft models, all while maintaining the integrated safety profile." J***n P.

"The final deliverables from Creative Biolabs included highly detailed validation reports, specifically documenting the iCas9 kill kinetics. This documentation significantly streamlined the safety section of our filing, saving us months of validation work compared to what we budgeted for." A***y L.

How to Contact Us?

Our solid tumor targeting CAR-T development service, integrated with the iCas9 suicide gene system, is designed to achieve precise regulation and enhanced safety control, yielding candidate therapies with high potency and specificity.

For further details or to discuss your project needs, please feel free to contact our team.

Reference

1. Gargett, Tessa, and Michael P Brown. "The inducible caspase-9 suicide gene system as a "safety switch" to limit on-target, off-tumor toxicities of chimeric antigen receptor T cells." Frontiers in pharmacology vol. 5 235. Distributed under Open Access License CC BY 4.0, without modification. https://doi.org/10.3389/fphar.2014.00235.